April Armstrong

1 month ago | healio.com | Gabrielle Capaldo |Carol L. DiBerardino |April Armstrong

Key takeaways: Patients treated with delgocitinib were categorized as achieving a deep, consistent or maintained response. In total, 48% achieved deep responses, more than 24% reached consistent responses and about 33% maintained responses. ORLANDO — A subset of patients treated with delgocitinib cream 20 mg/g for moderate to severe chronic eczema achieved a “super-response,” by week 16, according to a presenter at the American Academy of Dermatology Annual Meeting. According to April W.

Jan 22, 2025 | dialnet.unirioja.es | Joel M. Gelfand |April Armstrong |Henry Lim |Steven Feldman

Ayuda Buscar en la ayuda Buscar en la ayuda Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis: The LITE Randomized Clinical Trial Autores: Joel M. Gelfand, April W. Armstrong, Henry W. Lim, Steven R. Feldman, Sandra M. Johnson, W. C. Cole Claiborne, Robert E. Kalb, Jeannette Jakus, Aaron R. Mangold, R. Hal Flowers, Tina Bhutani, John R. Durkin, Jerry Bagel, Scott Fretzin, Michael P. Sheehan, James Krell, Margo J.

Nov 18, 2024 | healio.com | Gabrielle Capaldo |April Armstrong |Kristen Dowd

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: The report included details on social stigma, health disparities and comorbidities associated with patients with psoriasis.

Oct 22, 2024 | dermatologytimes.com | April Armstrong |Kassim Rahawi |Wendell Valdecantos |Stella Kyaw-Soe

NewsArticleSponsored ContentOctober 22, 2024Author(s):,Given the complexity of the underlying inflammation in patients with AD, an increased understanding of the OX40L pathway can improve our understanding of AD pathogenesis. Disclosure: This is a nonpromotional article for healthcare professionals and is sponsored by Sanofi. The author was compensated by Sanofi in connection with this article.

Oct 4, 2024 | mdedge.com | April Armstrong |Robert Bissonnette |Raj Chovatiya |Tina Bhutani

Psoriasis is a chronic inflammatory disease affecting approximately 8 million adults in the United States and 2% of the global population.1,2 Psoriasis causes pain, itching, and disfigurement and is associated with a physical, psychological, and economic burden that substantially affects health-related quality of life.3-5 Setting treatment goals and treating to target are evidence-based approaches that have been successfully applied to several chronic diseases to improve patient outcomes,...